Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:49 UTC |
---|
Update Date | 2022-03-07 02:51:40 UTC |
---|
HMDB ID | HMDB0014576 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Trifluridine |
---|
Description | Trifluridine is only found in individuals that have used or taken this drug. It is an antiviral derivative of thymidine used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557)The mechanism of action of trifluridine has not been fully determined, but appears to involve the inhibition of viral replication. Trifluridine does this by incorporating into viral DNA during replication, which leads to the formation of defective proteins and an increased mutation rate. This drug also reversibly inhibits thymidylate synthetase, an enzyme that is necessary for DNA synthesis. |
---|
Structure | OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(C(=O)NC1=O)C(F)(F)F InChI=1S/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)/t5-,6+,7+/m0/s1 |
---|
Synonyms | Value | Source |
---|
5-(Trifluoromethyl)deoxyuridine | ChEBI | 5-Trifluoromethyl-2-deoxyuridine | ChEBI | Trifluoromethyldeoxyuridine | ChEBI | Trifluorothymidine | ChEBI | Trifluorothymine deoxyriboside | ChEBI | Trifluridina | ChEBI | Trifluridinum | ChEBI | Viroptic | ChEBI | Elcon brand OF trifluridine | HMDB | Viromidin | HMDB | 5-Trifluoromethyl-2'-deoxyuridine | HMDB | Allergan brand OF trifluridine | HMDB | Mann brand OF trifluridine | HMDB | Monarch brand OF trifluridine | HMDB | Tramedico brand OF trifluridine | HMDB | Trifluoridine | HMDB | 2'-Deoxy-5-(trifluoromethyl)uridine | HMDB | 5 Trifluoromethyl 2' deoxyuridine | HMDB | TFT Ophtiole | HMDB | Triflumann | HMDB | Virophta | HMDB |
|
---|
Chemical Formula | C10H11F3N2O5 |
---|
Average Molecular Weight | 296.1999 |
---|
Monoisotopic Molecular Weight | 296.062006087 |
---|
IUPAC Name | 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)-1,2,3,4-tetrahydropyrimidine-2,4-dione |
---|
Traditional Name | trifluridine |
---|
CAS Registry Number | 70-00-8 |
---|
SMILES | OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(C(=O)NC1=O)C(F)(F)F |
---|
InChI Identifier | InChI=1S/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)/t5-,6+,7+/m0/s1 |
---|
InChI Key | VSQQQLOSPVPRAZ-RRKCRQDMSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as pyrimidine 2'-deoxyribonucleosides. Pyrimidine 2'-deoxyribonucleosides are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at position 2. |
---|
Kingdom | Organic compounds |
---|
Super Class | Nucleosides, nucleotides, and analogues |
---|
Class | Pyrimidine nucleosides |
---|
Sub Class | Pyrimidine 2'-deoxyribonucleosides |
---|
Direct Parent | Pyrimidine 2'-deoxyribonucleosides |
---|
Alternative Parents | |
---|
Substituents | - Pyrimidine 2'-deoxyribonucleoside
- Pyrimidone
- Hydroxypyrimidine
- Hydropyrimidine
- Pyrimidine
- Tetrahydrofuran
- Heteroaromatic compound
- Secondary alcohol
- Oxacycle
- Azacycle
- Organoheterocyclic compound
- Hydrocarbon derivative
- Alcohol
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Primary alcohol
- Organooxygen compound
- Organonitrogen compound
- Organofluoride
- Organohalogen compound
- Organic nitrogen compound
- Alkyl halide
- Alkyl fluoride
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 186 - 189 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 6.69 g/L | Not Available | LogP | -0.7 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Trifluridine,1TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=C(C(F)(F)F)C(=O)[NH]C2=O)C[C@@H]1O | 2033.2 | Semi standard non polar | 33892256 | Trifluridine,1TMS,isomer #2 | C[Si](C)(C)O[C@H]1C[C@H](N2C=C(C(F)(F)F)C(=O)[NH]C2=O)O[C@@H]1CO | 2068.1 | Semi standard non polar | 33892256 | Trifluridine,1TMS,isomer #3 | C[Si](C)(C)N1C(=O)C(C(F)(F)F)=CN([C@H]2C[C@H](O)[C@@H](CO)O2)C1=O | 2160.2 | Semi standard non polar | 33892256 | Trifluridine,2TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=C(C(F)(F)F)C(=O)[NH]C2=O)C[C@@H]1O[Si](C)(C)C | 2082.5 | Semi standard non polar | 33892256 | Trifluridine,2TMS,isomer #2 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=C(C(F)(F)F)C(=O)N([Si](C)(C)C)C2=O)C[C@@H]1O | 2206.4 | Semi standard non polar | 33892256 | Trifluridine,2TMS,isomer #3 | C[Si](C)(C)O[C@H]1C[C@H](N2C=C(C(F)(F)F)C(=O)N([Si](C)(C)C)C2=O)O[C@@H]1CO | 2226.4 | Semi standard non polar | 33892256 | Trifluridine,3TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=C(C(F)(F)F)C(=O)N([Si](C)(C)C)C2=O)C[C@@H]1O[Si](C)(C)C | 2208.3 | Semi standard non polar | 33892256 | Trifluridine,3TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=C(C(F)(F)F)C(=O)N([Si](C)(C)C)C2=O)C[C@@H]1O[Si](C)(C)C | 2342.0 | Standard non polar | 33892256 | Trifluridine,3TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=C(C(F)(F)F)C(=O)N([Si](C)(C)C)C2=O)C[C@@H]1O[Si](C)(C)C | 2242.7 | Standard polar | 33892256 | Trifluridine,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=C(C(F)(F)F)C(=O)[NH]C2=O)C[C@@H]1O | 2280.6 | Semi standard non polar | 33892256 | Trifluridine,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)O[C@H]1C[C@H](N2C=C(C(F)(F)F)C(=O)[NH]C2=O)O[C@@H]1CO | 2301.7 | Semi standard non polar | 33892256 | Trifluridine,1TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)N1C(=O)C(C(F)(F)F)=CN([C@H]2C[C@H](O)[C@@H](CO)O2)C1=O | 2372.5 | Semi standard non polar | 33892256 | Trifluridine,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=C(C(F)(F)F)C(=O)[NH]C2=O)C[C@@H]1O[Si](C)(C)C(C)(C)C | 2548.5 | Semi standard non polar | 33892256 | Trifluridine,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=C(C(F)(F)F)C(=O)N([Si](C)(C)C(C)(C)C)C2=O)C[C@@H]1O | 2624.2 | Semi standard non polar | 33892256 | Trifluridine,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)O[C@H]1C[C@H](N2C=C(C(F)(F)F)C(=O)N([Si](C)(C)C(C)(C)C)C2=O)O[C@@H]1CO | 2637.1 | Semi standard non polar | 33892256 | Trifluridine,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=C(C(F)(F)F)C(=O)N([Si](C)(C)C(C)(C)C)C2=O)C[C@@H]1O[Si](C)(C)C(C)(C)C | 2858.6 | Semi standard non polar | 33892256 | Trifluridine,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=C(C(F)(F)F)C(=O)N([Si](C)(C)C(C)(C)C)C2=O)C[C@@H]1O[Si](C)(C)C(C)(C)C | 2940.3 | Standard non polar | 33892256 | Trifluridine,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=C(C(F)(F)F)C(=O)N([Si](C)(C)C(C)(C)C)C2=O)C[C@@H]1O[Si](C)(C)C(C)(C)C | 2551.1 | Standard polar | 33892256 |
|
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Trifluridine GC-MS (Non-derivatized) - 70eV, Positive | splash10-002f-9070000000-5b0bc8f23d4e75143939 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Trifluridine GC-MS (2 TMS) - 70eV, Positive | splash10-0v70-9845200000-37084cd9faa19fab8cdd | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Trifluridine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trifluridine 10V, Positive-QTOF | splash10-001i-0900000000-98b3bdac019c141f7f2b | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trifluridine 20V, Positive-QTOF | splash10-001i-0910000000-88c39b37d01c15092d5b | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trifluridine 40V, Positive-QTOF | splash10-001r-1900000000-6af805305211581c822e | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trifluridine 10V, Negative-QTOF | splash10-0w2a-1490000000-06d5a9ab5df20c112030 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trifluridine 20V, Negative-QTOF | splash10-0a6r-0790000000-aca1588a5498c0e36172 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trifluridine 40V, Negative-QTOF | splash10-0006-5900000000-3142b258f9393903ca54 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trifluridine 10V, Negative-QTOF | splash10-002b-0090000000-9941fbdce182b1697ae3 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trifluridine 20V, Negative-QTOF | splash10-0ufr-1920000000-0b7d290fcb81239751b5 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trifluridine 40V, Negative-QTOF | splash10-0006-9500000000-c59f899250e30f03cf63 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trifluridine 10V, Positive-QTOF | splash10-0002-0290000000-d2c6f13535b38e719f66 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trifluridine 20V, Positive-QTOF | splash10-001i-0910000000-2f204a289423b2c2048d | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trifluridine 40V, Positive-QTOF | splash10-053r-2960000000-d74ea6cb75e5abd92cdb | 2021-09-22 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00432 | | details | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00432 | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB00432 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 6020 |
---|
KEGG Compound ID | Not Available |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Trifluridine |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 6256 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 75179 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Overman MJ, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff P, Xiong H, Abbruzzese JL: Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008 Oct;26(8):794-9. doi: 10.1080/07357900802087242. [PubMed:18798063 ]
- Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, Kuwata K, Hoff PM: Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer. 2006 Sep 15;107(6):1383-90. [PubMed:16902987 ]
- Temmink OH, Prins HJ, van Gelderop E, Peters GJ: The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells. Br J Cancer. 2007 Jan 15;96(1):61-6. Epub 2006 Dec 19. [PubMed:17179993 ]
- O'Brien WJ, Taylor JL: Therapeutic response of herpes simplex virus-induced corneal edema to trifluridine in combination with immunosuppressive agents. Invest Ophthalmol Vis Sci. 1991 Aug;32(9):2455-61. [PubMed:1907950 ]
- Kuster P, Taravella M, Gelinas M, Stepp P: Delivery of trifluridine to human cornea and aqueous using collagen shields. CLAO J. 1998 Apr;24(2):122-4. [PubMed:9571274 ]
- Costin D, Dogaru M, Popa AS, Cijevschi I: [Trifluridine therapy in herpetic in keratitis]. Rev Med Chir Soc Med Nat Iasi. 2004 Apr-Jun;108(2):409-12. [PubMed:15688823 ]
|
---|